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1. INTRODUCTION {#brb31312-sec-0006}
===============

Chemotherapy‐induced peripheral neuropathy (CIPN) is a common side effect of taxane‐ and platinum‐based chemotherapy, with prevalence ranging from 12%--96% (Eckhoff, Knoop, Jensen, & Ewertz, [2015](#brb31312-bib-0007){ref-type="ref"}; Osmani et al., [2012](#brb31312-bib-0023){ref-type="ref"}; Seretny et al., [2014](#brb31312-bib-0027){ref-type="ref"}). The impact of CIPN on patients' quality of life can be significant (Ezendam et al., [2014](#brb31312-bib-0008){ref-type="ref"}; Mols, Beijers, Vreugdenhil, & Poll‐Franse, [2014](#brb31312-bib-0022){ref-type="ref"}; Seretny et al., [2014](#brb31312-bib-0027){ref-type="ref"}). CIPN may be challenging for clinicians to diagnose, assess and manage, especially in patients with co‐existing or preexisting conditions or disorders that involve the peripheral nervous system (Hausheer, Schilsky, Bain, Berghorn, & Lieberman, [2006](#brb31312-bib-0011){ref-type="ref"}). A general predisposition for developing CIPN is observed in nerves previously damaged by diabetes mellitus, alcohol, or inherited neuropathy (Quasthoff & Hartung, [2002](#brb31312-bib-0026){ref-type="ref"}). Thyroid dysfunction, metabolic and infectious diseases (i.e., hepatitis B or C, poliomyelitis, HIV), vitamin deficiencies (i.e., B12, B1, B6), and monoclonal gammopathy have also been implicated in the pathogenesis of CIPN (Armstrong, Almadrones, & Gilbert, [2005](#brb31312-bib-0002){ref-type="ref"}; Kaley & DeAngelis, [2009](#brb31312-bib-0014){ref-type="ref"}). Many medications that are commonly used in cancer patients, such as metronidazole, misonidazole, sulfasalazine, or phenytoin, are all documented to be associated with some degree of peripheral neurotoxicity (Hausheer et al., [2006](#brb31312-bib-0011){ref-type="ref"}).

Research around risk factors for CIPN has increased over recent years, although at times findings are inconsistent or a limited pool of potential factors is assessed. In a large study (*n* = 3,106), worse neurotoxicity was observed in colorectal cancer patients, those with longer duration of cancer, on current therapy, older patients, and in African Americans (Lewis et al., [2015](#brb31312-bib-0017){ref-type="ref"}). Being obese and having more insomnia severity, anxiety, and depression were all associated with CIPN in other studies (Bao et al., [2016](#brb31312-bib-0004){ref-type="ref"}; Simon, Danso, Alberico, Basch, & Bennett, [2017](#brb31312-bib-0028){ref-type="ref"}). Older age, lower income, higher BMI, comorbidities, being born prematurely, higher cumulative dose of chemotherapy, and poorer functional status were also predictive of CIPN (Miaskowski et al., [2017](#brb31312-bib-0019){ref-type="ref"}). Diabetes was also shown to be predictor of CIPN (Ottaiano et al., [2016](#brb31312-bib-0024){ref-type="ref"}) although other studies have found no such link (Pereira et al., [2016](#brb31312-bib-0025){ref-type="ref"}; Simon et al., [2017](#brb31312-bib-0028){ref-type="ref"}). However, many of the potential predictors of CIPN have not been fully investigated to date. Hence, the aim of this study was to assess the relative contribution of a wider range of risk factors in the development of CIPN, providing a stronger explanatory model, and further explore the potential link between CIPN and other symptoms.

2. MATERIALS AND METHODS {#brb31312-sec-0007}
========================

2.1. Design {#brb31312-sec-0008}
-----------

This analysis used data from the 6‐month CIPN assessment after starting chemotherapy from a larger prospective observational study on CIPN prevalence and quality of life (Molassiotis et al., [2019](#brb31312-bib-0021){ref-type="ref"}), focusing on one of the primary objectives of the study.

2.2. Sample and settings {#brb31312-sec-0009}
------------------------

The sample included patients receiving platinum‐based chemotherapy (primarily cisplatin) and taxane‐based chemotherapy (primarily docetaxel) for the treatment of breast, lung, ovarian, gastrointestinal, head & neck as well as urinary tract cancers. Data were collected from specialist oncology clinics in three countries/regions (Hong Kong, Singapore, and Manchester in the UK). The study was approved by the ethics committees of the Hong Kong Polytechnic University, Hong Kong; Central Cluster of the Hospital Authority, Hong Kong; The National University Hospital; Singapore; The University of Manchester, Manchester, UK; and the Central Manchester Research and Ethics Committee. All participants have provided written informed consent.

3. PROCEDURES {#brb31312-sec-0010}
=============

Eligible patients were identified and approached at hospital outpatients clinics. Those who agreed to participate and provided informed signed consent completed all the baseline measurements including personal characteristics and presence of potential risk factors as identified in the literature. Clinical data were obtained from the medical records as well as information on medication used and past medical history. Participants in the larger project underwent a neuropathy assessment repeated at each cycle of chemotherapy (up to six cycles), 6 months, 9 months, and 12 months postchemotherapy. For the current analysis, data from the 6‐month assessment were used as it had the highest number of patients across all assessments and the highest incidence of CIPN. Ethical approval was obtained from each site before commencing the study.

4. OUTCOME MEASURES {#brb31312-sec-0011}
===================

4.1. Risk assessment {#brb31312-sec-0012}
--------------------

Potential risk factors identified previously in the literature (Armstrong et al., [2005](#brb31312-bib-0002){ref-type="ref"}; Hauseer et al., [2006](#brb31312-bib-0011){ref-type="ref"}; Kaley & DeAngelis, [2009](#brb31312-bib-0014){ref-type="ref"}; Miaskowski et al., [2017](#brb31312-bib-0019){ref-type="ref"}; Ottaiano et al., [2016](#brb31312-bib-0024){ref-type="ref"}; Quasthoff & Hartung, [2002](#brb31312-bib-0026){ref-type="ref"}) were examined for their impact in the development of CIPN. These included: Diagnosis with acquired or hereditary neuropathy such as diabetes, renal disease, hypothyroidism, connective tissue disease. Prior history of neuropathy or family history of neuropathy; vitamin deficiencies (Hershman et al., [2016](#brb31312-bib-0012){ref-type="ref"}; Ottaiano et al., [2016](#brb31312-bib-0024){ref-type="ref"}; Seretny et al., [2014](#brb31312-bib-0027){ref-type="ref"}).Diagnosis with current or previous infectious diseases (HIV; Poliomyelitis; Hepatitis B or C; Armstrong et al., [2005](#brb31312-bib-0002){ref-type="ref"}; Kaley & DeAngelis, [2009](#brb31312-bib-0014){ref-type="ref"}; Seretny et al., [2014](#brb31312-bib-0027){ref-type="ref"}).Neurotoxic medication history (a list of 51 medications linked with neurotoxicity, such as cyclosporine, vancomycin, cimetidine, etc; Hauseer et al., [2006](#brb31312-bib-0011){ref-type="ref"}; Kaley & DeAngelis, [2009](#brb31312-bib-0014){ref-type="ref"}; Quasthoff & Hartung, [2002](#brb31312-bib-0026){ref-type="ref"}).Personal and treatment characteristics:oAge (Lewis et al., [2015](#brb31312-bib-0017){ref-type="ref"}; Miaskowski et al., [2017](#brb31312-bib-0019){ref-type="ref"}, [2018](#brb31312-bib-0020){ref-type="ref"}).oDisease site (Quasthoff & Hartung, [2002](#brb31312-bib-0026){ref-type="ref"}; Seretny et al., [2014](#brb31312-bib-0027){ref-type="ref"}; Simon et al., [2017](#brb31312-bib-0028){ref-type="ref"}).oChemotherapy type (taxanes; platinum‐based chemotherapy; combination of taxanes and platinum‐based chemotherapy), number of chemotherapy cycles, and cumulative dosage of each neurotoxic chemotherapy drug (Kaley & DeAngelis, [2009](#brb31312-bib-0014){ref-type="ref"}; Quasthoff & Hartung, [2002](#brb31312-bib-0026){ref-type="ref"}; Simon et al., [2017](#brb31312-bib-0028){ref-type="ref"}).oSmoking history (never smoked; current smoker; ex‐smoker; Kawakami et al., [2012](#brb31312-bib-0015){ref-type="ref"}; Seretny et al., [2014](#brb31312-bib-0027){ref-type="ref"}).oHistory of alcohol intake (Pereira et al., [2016](#brb31312-bib-0025){ref-type="ref"}) (drinks per day (number) using an explanatory diagram on quantity (i.e., small glass of wine (120 ml) = 1 drink, etc).oDietary history (servings of fruits and vegetables per day with explanations, i.e., 1 serve = 1 fruit) (Greenlee et al., [2016](#brb31312-bib-0010){ref-type="ref"}).

4.2. NEUROTOXICITY ASSESSMENT {#brb31312-sec-0013}
-----------------------------

The National Cancer Institute -- Common Terminology Criteria for Adverse Events (NCI‐CTCAE) version 4.03 is a physician‐rated grading system that includes criteria and definitions for quantifying and grading CIPN. This grading scale comprises two items, with a sensory and a motor assessment and utilizes a 5‐point scale ranging from grade 1 to grade 5.The WHO criterion is also a physician‐rated CIPN item, and includes paresthesia, reflex decreases and extend of motor loss as parameters (WHO, [1979](#brb31312-bib-0033){ref-type="ref"}).

These two assessments were completed using both a checklist of neuropathy‐related indications and physical/neurological examination to aid in the diagnosis. Also, a new composite variable (combined scale, supported by the combined scale\'s Cronbach alpha of 0.74, intraclass correlation of 0.74 and item‐to‐item correlations of 0.41--0.61, *p* \< 0.01) was also created with a combination of the above three items, in order to have maximum variation in the data, as the two scales were identifying varying prevalence of CIPN at different patients (the highest prevalence rate with the WHO criterion item). This combined outcome variable was flagged as having CIPN when at least one of the three items used in the assessment of CIPN indicated so, and it was used in the risk factor analysis.

4.3. Symptom burden {#brb31312-sec-0014}
-------------------

This variable responds to a secondary objective of the study to explore any links between CIPN and other symptoms. In order to estimate symptom burden, we used data from the single‐item symptom measures (items 8, 9, 11--25 of the European Organization for Research and Treatment (EORTC) QLQ‐C30. It incorporates nine multi‐item scales to assess quality of life: five functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality‐of‐life scale (Aaronson et al., [1993](#brb31312-bib-0001){ref-type="ref"}). In order to estimate symptom burden, we used data from the single‐item symptom measures (items 8,9, 11--25 of the scale, including pain, tiredness, appetite loss, breathlessness, nausea, vomiting, constipation, diarrhea, cognitive impairment, psychological symptoms) after transforming them to 0--100 scores, thus creating a new predictor variable of "symptom burden". This scale has been validated in China (Wan et al., [2008](#brb31312-bib-0032){ref-type="ref"}) and Singapore (Tan et al., [2014](#brb31312-bib-0030){ref-type="ref"}). Its Cronbach\'s alpha in our sample was 0.90.

5. DATA ANALYSIS {#brb31312-sec-0015}
================

Descriptive statistics were used to summarize the data. Chi‐square analysis assessed differences in categorical variables while Student\'s *t* tests were used for comparing continuous variables. Logistic regression models were used for the main risk factor analysis. The relevant covariates for initial model inclusion were identified using a multivariate analysis, with rules (*p*‐values \< 0.20) for retaining variables in the model. This was followed by the final model which only included significant (defined above) variables. This is a recommended approach for removing unimportant covariates so that a more manageable set of variables can be used with more complex multivariate statistical techniques (Lee, [2014](#brb31312-bib-0016){ref-type="ref"}). A multilevel logistic regression analyses took place taking account of center effect and time since last cycle of chemotherapy, to develop the predictive model for CIPN. Data were analyzed using SPSS v.21.

6. RESULTS {#brb31312-sec-0016}
==========

6.1. Sample characteristics {#brb31312-sec-0017}
---------------------------

Data from 255 participants were available for analysis at the 6‐month assessment of CIPN (chosen as this point had the highest CIPN rate and highest number of participants). The larger study had 343 patients at baseline and 2,399 observations in total, although numbers decreased over time due to patients discontinuing chemotherapy, patient death, or relocation of patients. There were 162 participants from Hong Kong (63.5%), 78 from Singapore (30.6%), and 15 from the UK (5.9%). The majority were breast cancer patients followed by lung cancer and gynecological cancer patients, receiving adjuvant chemotherapy, and at stage II or III of their cancer. Sample characteristics are shown in Tables [1](#brb31312-tbl-0001){ref-type="table"} and [2](#brb31312-tbl-0002){ref-type="table"}. Analysis with individual chemotherapy types (i.e., docetaxel or cisplatin) was done initially separately, and as common risk factor patterns were observed across protocols, the whole data was subsequently analyzed and reported together.

###### 

Chemotherapy‐induced peripheral neuropathy and its risk factors in categorical variables (*n* = 255)

  Variable                     Frequency     Chemotherapy‐induced peripheral neuropathy (CIPN) frequency and percentage in each scale                             
  ---------------------------- ------------- ------------------------------------------------------------------------------------------ ------------ ------------ ------------
  Overall                      255 (100%)    36 (14.1%)                                                                                 33 (12.9%)   45 (17.6%)   68 (26.7%)
  Race                                                                                                                                                            
  Chinese                      210 (82.4%)   30 (14.3%)                                                                                 26 (12.4%)   34 (16.2%)   55 (26.2%)
  Non‐Chinese Asians           23 (9.0%)     3 (13.0%)                                                                                  4 (17.4%)    9 (39.1%)    9 (39.1%)
  Caucasian                    22 (8.6%)     3 (13.6%)                                                                                  3 (13.6%)    2 (9.1%)     4 (18.2%)
  *p‐value*                                  0.98                                                                                       0.79         0.01         0.26
  Chemotherapy group                                                                                                                                              
  Taxanes                      123 (48.2%)   25 (20.3%)                                                                                 24 (19.5%)   30 (24.4%)   46 (37.4%)
  Platinum                     64 (25.1%)    4 (6.3%)                                                                                   3 (4.7%)     6 (9.4%)     7 (10.9%)
  Combined                     68 (26.7%)    7 (10.3%)                                                                                  6 (8.8%)     9 (13.2%)    15 (22.1%)
  *p‐value*                                  0.02                                                                                       0.008        0.02         \<0.001
  Treatment intent                                                                                                                                                
  Radical (adjuvant)           157 (61.6%)   24 (15.3%)                                                                                 19 (12.1%)   22 (14.0%)   39 (24.8%)
  Radical (neoadjuvant)        43 (16.9%)    6 (14.0%)                                                                                  7 (16.3%)    10 (23.3%)   14 (32.6%)
  Radical (concurrent)         14 (5.5%)     1 (7.1%)                                                                                   1 (7.1%)     0 (0.0%)     1 (7.1%)
  Palliative                   41 (16.1%)    5 (12.2%)                                                                                  6 (14.6%)    13 (31.7%)   14 (34.1%)
  *p‐value*                                  0.83                                                                                       0.79         0.01         0.18
  Chemotherapy protocol                                                                                                                                           
  Paclitaxel                   27 (10.6%)    14 (51.9%)                                                                                 15 (55.6%)   14 (51.9%)   15 (55.6%)
  Docetaxel                    96 (37.6%)    16 (16.7%)                                                                                 31 (32.3%)   16 (16.7%)   31 (32.3%)
  Cisplatin                    41 (16.1%)    2 (4.9%)                                                                                   3 (7.3%)     2 (4.9%)     3 (7.3%)
  Oxaliplatin                  20 (7.8%)     4 (20.0%)                                                                                  4 (20.0%)    4 (20.0%)    4 (20.0%)
  Carboplatin and docetaxel    28 (11.0%)    2 (7.1%)                                                                                   3 (10.7%)    2 (7.1%)     3 (10.7%)
  Carboplatin and paclitaxel   34 (13.3%)    7 (20.6%)                                                                                  12 (35.3%)   7 (20.6%)    12 (35.3%)
  *p*‐value                                  0.13                                                                                       0.03         \<0.001      \<0.001
  Diagnosis                                                                                                                                                       
  Ovarian                      25 (9.8%)     4 (16.0%)                                                                                  4 (16.0%)    3 (12.0%)    7 (28.0%)
  Lung                         28 (11.0%)    1 (3.6%)                                                                                   1 (3.6%)     1 (3.6%)     1 (3.6%)
  Head and neck                17 (6.7%)     1 (5.9%)                                                                                   1 (5.9%)     1 (5.9%)     2 (11.8%)
  Breast                       146 (57.3%)   25 (17.1%)                                                                                 23 (15.8%)   32 (21.9%)   49 (33.6%)
  Colorectal                   15 (5.9%)     0 (0.0%)                                                                                   0 (0.0%)     3 (20.0%)    0 (0.0%)
  Others                       24 (9.4%)     5 (20.8%)                                                                                  4 (16.7%)    5 (20.8%)    5 (20.8%)
  *p‐value*                                  0.15                                                                                       0.25         0.15         0.02
  Stage                                                                                                                                                           
  I                            41 (16.1%)    6 (14.6%)                                                                                  5 (12.2%)    3 (7.3%)     9 (22.0%)
  II                           79 (31.0%)    14 (17.7%)                                                                                 10 (12.7%)   17 (21.5%)   24 (30.4%)
  III                          84 (32.9%)    8 (9.5%)                                                                                   9 (10.7%)    11 (13.1%)   18 (21.4%)
  IV                           51 (20.0%)    8 (15.7%)                                                                                  9 (17.6%)    14 (27.5%)   17 (33.3%)
  *p‐value*                                  0.49                                                                                       0.71         0.04         0.34
  Metronidazole                12 (4.7%)     3 (25.0%)                                                                                  2 (16.7%)    3 (25.0%)    5 (41.7%)
  *p‐value*                                  0.23                                                                                       0.48         0.45         0.23
  Statins                      37 (14.5%)    7 (18.9%)                                                                                  9 (24.3%)    9 (24.3%)    15 (40.5%)
  *p‐value*                                  0.25                                                                                       0.03         0.25         0.04
  Gender                                                                                                                                                          
  Male                         49 (19.2%)    4 (8.2%)                                                                                   3 (6.1%)     8 (16.3%)    9 (18.4%)
  Female                       206 (80.8%)   32 (15.5%)                                                                                 30 (14.6%)   37 (18.0%)   59 (28.6%)
  *p‐value*                                  0.18                                                                                       0.11         0.79         0.14
  Smoking history                                                                                                                                                 
  Never                        199 (78.0%)   29 (14.6%)                                                                                 27 (13.6%)   36 (18.1%)   57 (28.6%)
  Current                      7 (2.7%)      1 (14.3%)                                                                                  1 (14.3%)    3 (42.9%)    3 (42.9%)
  Ex‐smoker                    49 (19.2%)    6 (12.2%)                                                                                  5 (10.2%)    6 (12.2%)    8 (16.3%)
  *p‐value*                                  0.92                                                                                       0.82         0.13         0.13
  Diabetes                     37 (14.5%)    5 (13.5%)                                                                                  8 (21.6%)    7 (18.9%)    12 (32.4%)
  *p‐value*                                  0.91                                                                                       0.09         0.83         0.39
  Hypothyroidism               6 (2.4%)      0 (0.0%)                                                                                   0 (0.0%)     1 (16.7%)    1 (16.7%)
  *p‐value*                                  0.40                                                                                       0.43         0.71         0.58
  History of neuropathy        13 (5.1%)     6 (46.2%)                                                                                  4 (30.8%)    0 (0.0%)     6 (46.2%)
  *p‐value*                                  0.001                                                                                      0.049        0.09         0.10
  Hepatitis B or C             13 (5.1%)     1 (7.7%)                                                                                   3 (23.1%)    4 (30.8%)    5 (38.5%)
  *p‐value*                                  0.50                                                                                       0.26         0.20         0.32
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###### 

Risk factors of chemotherapy‐induced peripheral neuropathy in univariate analysis of continuous variables (*n* = 255)

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                 Overall          Chemotherapy‐induced peripheral neuropathy with each scale used                                                                                                                                                   
  ---------------------------------------- ---------------- ----------------------------------------------------------------- ---------------- ------ ---------------- ---------------- ------- ---------------- ---------------- --------- ---------------- ---------------- ---------
  Age                                      54.2 (9.2)       57.4 (8.3)                                                        53.6 (9.3)       0.02   57.7 (8.3)       53.6 (9.2)       0.02    56.7 (9.2)       53.6 (9.1)       0.04      56.4 (8.9)       53.4 (9.2)       0.02

  Cumulative dose                                                                                                                                                                                                                                                              

  Oxaliplatin\                             718.7 (288.5)\   721.7\                                                            718.5 (296.4)\   0.99   721.8\           718.5 (296.4)\   0.99    862.5 (109.4)\   682.7 (310.1)\   0.28      862.5 (109.4)\   682.7 (310.1)\   0.28
  (mg/m^2^)                                (*n* = 20)       (*n* = 1)                                                         (*n* = 19)              (*n* = 1)        (*n* = 19)               (*n* = 4)        (*n* = 16)                 (*n* = 4)        (*n* = 16)       

  Carboplatin AUC                          27.2 (7.4)\      28.0 (3.8)\                                                       27.1 (7.7)\      0.76   28.3 (4.1)\      27.1 (7.6)\      0.70    25.8 (8.9)\      27.4 (7.2)\      0.55      26.6 (7.2)\      27.4 (7.5)\      0.71
                                           (*n* = 66)       (*n* = 7)                                                         (*n* = 59)              (*n* = 6)        (*n* = 60)               (*n* = 9)        (*n* = 57)                 (*n* = 15)       (*n* = 51)       

  Cisplatin\                               215.8 (145.9)\   117.3 (28.3)\                                                     223.5 (148.8)\   0.23   126.0 (33.9)\    220.4 (148.1)\   0.38    101.0 (1.4)\     221.7 (147.3)\   0.26      117.3 (28.3)\    223.5 (148.7)\   0.23
  (mg/m^2^)                                (*n* = 41)       (*n* = 3)                                                         (*n* = 38)              (*n* = 2)        (*n* = 39)               (*n* = 2)        (*n* = 39)                 (*n* = 3)        (*n* = 38)       

  Paclitaxel\                              963.3 (219.7)\   976.5 (300.0)\                                                    960.7 (203.5)\   0.83   984.1 (274.2)\   958.2 (207.0)\   0.71    965.2 (294.1)\   962.4 (178.9)\   0.96      982.2 (263.9)\   950.2 (185.8)\   0.57
  (mg/m^2^)                                (*n* = 66)       (*n* = 11)                                                        (*n* = 55)              (*n* = 13)       (*n* = 53)               (*n* = 21)       (*n* = 45)                 (*n* = 27)       (*n* = 39)       

  Docetaxel\                               373.9 (75.8)\    380.3 (74.5)\                                                     372.6 (76.4)\    0.67   385.3 (67.9)\    372.1 (77.1)\    0.51    401.0 (60.9)\    369.3 (77.4)\    0.10      385.4 (68.5)\    369.5 (78.2)\    0.30
  (mg/m^2^)                                (*n* = 124)      (*n* = 21)                                                        (*n* = 103)             (*n* = 17)       (*n* = 107)              (*n* = 18)       (*n* = 106)                (*n* = 34)       (*n* = 90)       

  Alcohol intake                           0.2 (0.7)        0.0 (0.0)                                                         0.2 (0.7)        0.10   0.0 (0.0)        0.2 (0.7)        0.12    0.04 (0.3)       0.2 (0.7)        0.16      0.03 (0.2)       0.2 (0.8)        0.04

  Fruit intake                             1.6 (1.5)        1.7 (0.8)                                                         1.6 (1.6)        0.81   1.5 (0.7)        1.6 (1.6)        0.69    1.6 (0.7)        1.6 (1.6)        0.96      1.6 (0.7)        1.6 (1.7)        0.96

  Vegetable intake                         1.8 (1.5)        1.7 (0.8)                                                         1.8 (1.6)        0.66   1.6 (0.8)        1.8 (1.6)        0.36    1.7 (0.8)        1.8 (1.6)        0.78      1.7 (0.8)        1.8 (1.7)        0.67

  Number of chemotherapy cycles received   6.2 (3.0)        6.5 (3.3)                                                         6.2 (3.0)        0.51   7.2 (3.6)        6.1 (2.9)        0.049   8.3 (4.1)        5.8 (2.5)        \<0.001   7.5 (3.7)        5.8 (2.6)        \<0.001

  Symptom burden (total score)             24.4 (7.0)       26.3 (7.9)                                                        24.0 (6.8)       0.07   27.4 (8.2)       23.9 (6.7)       0.008   26.4 (9.6)       23.9 (6.2)       0.03      26.4 (8.5)       23.6 (6.2)       0.005
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Non‐Chinese Asians (primarily of Malay and Indian origin) had higher risk of developing neuropathy than Chinese or Caucasians, only when the WHO scale was used (*p* = 0.01). Also, patients receiving platinum‐based chemotherapy had lower risk of developing CIPN than those receiving taxane‐based chemotherapy (across all CIPN scales used). A particularly high incidence of developing CIPN was observed in patients receiving paclitaxel compared to all other chemotherapy protocols. For many medications in our list, there were not enough incidence of use (i.e., minimum of 5) to allow for further analysis. Metronidazole use had no statistically significant difference (although CIPN incidence was high in this group of patients). Use of statins was implicated in the development of sensory neuropathy and it was also statistically significant variable in the combined CIPN category (*p* = 0.04) and sensory neuropathy item (*p* = 0.03). Diabetes showed a trend (*p* = 0.09) with sensory CIPN only. History of neuropathy was predictive of CIPN when the CTCAE scale was used and showed trends when the WHO scale was used. Hepatitis was not a statistically significant risk factor, although CIPN incidence was high in this group of patients. Detailed data are presented in Table [1](#brb31312-tbl-0001){ref-type="table"}.

Table [2](#brb31312-tbl-0002){ref-type="table"} shows statistically significant predictors in continuous variables. Consistently (older) age and number of chemotherapy cycles received were significant risk factors. Alcohol intake was significant only when the combined scale was used. Symptom burden (mean of all symptoms from the EORTC scale) was also linked with CIPN in this univariate analysis, alongside a number of symptoms in at least the combined CIPN scale. These included pain interfering with daily activities (*p* = 0.02), trouble sleeping (*p* = 0.04), being tired (*p* = 0.01), appetite loss (*p* = 0.04), constipation (*p* = 0.001), worrying (*p* = 0.054), and difficulty remembering (*p* = 0.01). Fruit and vegetable intake were not linked with CIPN. A stepwise logistic regression just for the individual symptoms showed that two symptoms were linked with the higher risk of CIPN, namely difficulty remembering (OR = 1.61, *p* \< 0.05; 95% CI = 1.10--2.34) and constipation (OR = 2.06, *p* \< 0.01; 95% CI = 1.29--3.29).

The final multivariate logistic regression model (Table [3](#brb31312-tbl-0003){ref-type="table"}) of all univariate predictors with *p*‐value \< 0.20 observed in the previous analyses showed that patients receiving platinum‐based chemotherapy had lower risk of CIPN compared to those receiving taxane‐based chemotherapy; those with history of neuropathy had higher risk for (motor) CIPN, as well as older patients. Symptom burden had some contribution to (primarily to sensory) CIPN. Number of chemotherapy cycles received was also a strong predictor of CIPN. One unit of alcohol use decreased the risk of CIPN by 68% (only in the combined scale).

###### 

Logistic regression model of chemotherapy induced peripheral neuropathy‐related risk factors for each assessment scale used

  CTCAE‐motor scale       CTCAE‐sensory scale                                            WHO item                                 Combined CIPN scale                                                                                                                                                                                           
  ----------------------- -------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------------- ---------------------------------------- ------------------------------------------------------------- ---------------------------------------- -------------------------------------------------------------
  Chemotherapy group                                                                     Chemotherapy group                                                                                     Race                                                                                                   Chemotherapy group                        
  Taxanes                 Ref                                                            Taxanes                                  Ref                                                           Chinese                                  Ref                                                           Taxanes                                  Ref
  Platinum                0.27[\*](#brb31312-note-0003){ref-type="fn"} (0.07, 0.91)      Platinum                                 0.27 (0.07, 1.07)                                             Non‐Chinese Asians                       1.27 (0.35, 4.68)                                             Platinum                                 0.20[\*\*](#brb31312-note-0004){ref-type="fn"} (0.07, 0.58)
  Combined                0.46 (0.18, 1.21)                                              Combined                                 0.38 (0.14, 1.06)                                             Caucasian                                0.23 (0.03, 1.59)                                             Combined                                 0.51 (0.24, 1.08)
  Female                  1.72 (0.43, 6.95)                                              Female                                   2.36 (0.52, 10.75)                                            Chemotherapy group                                                                                     Female                                   1.01 (0.34, 3.04)
  History of neuropathy   8.36[\*\*](#brb31312-note-0004){ref-type="fn"} (1.74, 40.13)   History of neuropathy                    2.49 (0.59, 10.46)                                            Taxanes                                  Ref                                                           Smoking history                           
  Age                     1.02[\*](#brb31312-note-0003){ref-type="fn"} (1.02, 1.12)      Age                                      1.08[\*\*](#brb31312-note-0004){ref-type="fn"} (1.03, 1.13)   Platinum                                 0.25[\*](#brb31312-note-0003){ref-type="fn"} (0.08, 0.79)     Never                                    Ref
  Symptom burden          1.04 (0.99, 1.09)                                              Number of chemotherapy cycles received   1.12 (0.98, 1.29)                                             Combined                                 0.50 (0.20, 1.28)                                             Current                                  1.53 (0.26, 9.13)
                                                                                         Symptom burden                           1.06[\*](#brb31312-note-0003){ref-type="fn"} (1.01, 1.11)     Smoking history                                                                                        Ex‐smoker                                0.86 (0.31, 2.34)
                                                                                                                                                                                                Never                                    Ref                                                           History of neuropathy                    2.15 (0.56, 8.31)
                                                                                                                                                                                                Current                                  2.54 (0.42, 15.17)                                            Age                                      1.06[\*\*](#brb31312-note-0004){ref-type="fn"} (1.02, 1.10)
                                                                                                                                                                                                Ex‐smoker                                1.18 (0.36, 3.89)                                             Alcohol intake                           0.32[\*](#brb31312-note-0003){ref-type="fn"} (0.12, 0.86)
                                                                                                                                                                                                Hepatitis B or C                         3.93 (0.92, 16.83)                                            Number of chemotherapy cycles received   1.19[\*\*](#brb31312-note-0004){ref-type="fn"} (1.07, 1.32)
                                                                                                                                                                                                Age                                      1.06[\*](#brb31312-note-0003){ref-type="fn"} (1.01, 1.11)     Symptom burden                           1.06[\*](#brb31312-note-0003){ref-type="fn"} (1.01, 1.11)
                                                                                                                                                                                                Alcohol intake                           0.30 (0.07, 1.02)                                                                                       
                                                                                                                                                                                                Number of chemotherapy cycles received   1.24[\*\*](#brb31312-note-0004){ref-type="fn"} (1.07, 1.43)                                             
                                                                                                                                                                                                Symptom burden                           1.05 (0.995, 1.11)                                                                                      

Each regression model is presented in one column, the dependent variable is shown in the first row of the table and all variables were put in the regression as independent variables

*p* \< 0.05.

*p* \< 0.01.
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7. DISCUSSION {#brb31312-sec-0018}
=============

This study assessed CIPN clinical risk factors using a prospective design and a wide range of potential predictors. Overall CIPN incidence was lower in this study than that reported in the literature, and this has to do probably with the scales used; past studies have used quality of life scales to estimate CIPN, which often include a range of general/broader items to indicate neuropathy. Also, clinician‐based assessments, such as the NCI‐CTCAE tend to underestimate CIPN incidence (Dorsey et al., [2019](#brb31312-bib-0006){ref-type="ref"}). We have explained these reasons in more detail in the parent larger study (Molassiotis et al., [2019](#brb31312-bib-0021){ref-type="ref"}). However, in a systematic review it was shown that CIPN incidence at 6 months was 30% (Seretny et al., [2014](#brb31312-bib-0027){ref-type="ref"}) and our incidence in the combined tools was 26%. Key risk factors identified include older age, history of neuropathy, symptom burden, alcohol intake (cautiously accepted as a risk factor in this study due to the small number of events needing further clarification in the future) and number of chemotherapy cycles used. Patients receiving platinum‐based chemotherapy had 17%--27% less chance of developing CIPN compared to those receiving taxane‐based chemotheraopy. Risk factors were not always consistent across the scales used. This may reflect sensitivity or reliability issues with the various scales measuring CIPN. As the measurement tool(s) used in future risk factor research will be related with the identification of specific risk factors, it is important to use the most reliable and valid CIPN scale (Cavaletti et al., [2013](#brb31312-bib-0005){ref-type="ref"}; Dorsey et al., [2019](#brb31312-bib-0006){ref-type="ref"}) or a combination of scales to maximize the "pick up" rates of these tools that will include both patient‐reported outcomes and objective CIPN indicators, such as with the Total Neuropathy Score clinical version (TNSc) (McCrary et al., [2017](#brb31312-bib-0018){ref-type="ref"}).

Older age somewhat contributed to CIPN (6% more chances), supporting findings from past research (Bandos et al., [2018](#brb31312-bib-0003){ref-type="ref"}; Hershman et al., [2016](#brb31312-bib-0012){ref-type="ref"}; Miaskowski et al., [2017](#brb31312-bib-0019){ref-type="ref"}). History of neuropathy was a potential risk factor for motor neuropathy and its ORs were high in the other CIPN scales (but did not reach statistical significance). History of neuropathy was mainly linked with motor CIPN, with patients having such history being more than eight times at a higher risk for developing motor CIPN. The limited research of the past does not differentiate the role of this variable in the type of neuropathy, hence this is a novel finding. Statin use as a risk factor for CIPN is also another novel finding of this study, although this finding from univariate analysis was not sustained in the final model, likely because of the small number of patients receiving statins in this sample. This finding supports an earlier case‐control study on patients receiving statins, although the sample in the latter study was not focusing on cancer patients (Gaist et al., [2002](#brb31312-bib-0009){ref-type="ref"}). However, more recent work from a case‐control study showed that ever use of statins was not associated with a higher risk of polyneuropathy (Svendsen et al., [2017](#brb31312-bib-0029){ref-type="ref"}). This finding needs further elaboration in the future, although if a risk exists, it is probably minimal. Metronidazole use as a potential risk factor should also be investigated in the future, as the incidence of CIPN in this subgroup was high (up to 41.7%) and literature suggests sensory and autonomic neuropathy as a result of such use (Hobson‐Webb, Roach, & Donofrio, [2006](#brb31312-bib-0013){ref-type="ref"}), although the small number of such cases may have contributed to the nonsignificant results shown. Such future work should clearly delineate duration of use, dose and timing of use, which were not collected in our study and hence pose limitations in interpreting this result.

Symptom burden is a new variable implicated in the development of CIPN. Whether this finding is attributed to collinearity with CIPN or symptom burden influencing the development (and/or severity) of CIPN is not yet clear. Two particular symptoms (out of 18 assessed) had the strongest relationship with CIPN, including constipation and difficulty remembering. It may be that neuronal damage related to CIPN leads to constipation or cognitive deficits in patients. The link between autonomic neuropathy and constipation may be the result of neurogenic bowel/disautonomia or constipation may be one of the indications of constituent autonomic neuropathy. CIPN and cognitive changes such as difficulty remembering/"chemofog" may be link as a result of neuroinflammation postchemotherapy, which has been discussed as a potential mechanism for behavioral toxicities (Vichaya et al., [2015](#brb31312-bib-0031){ref-type="ref"}). It will be interesting to explore these assumptions in the future more concretely and have a more in‐depth understanding of the link between symptoms/symptom burden and CIPN. This finding is further supported by recent research showing that patients with CIPN had significantly poorer functional status (Miaskowski et al., [2017](#brb31312-bib-0019){ref-type="ref"}).

The role of (chronic) alcohol use in the development of CIPN is less clear, as contradictory findings have been presented in the literature, probably due to the inherent problems in measuring alcohol use accurately. Our findings suggest that no alcohol use had some protective effect in CIPN, but this was not consistent across all the scales used. Also, our sample had very few heavy drinkers and this may have impacted on the results. Alcohol use (as well as diabetes) may be associated with the development of neuropathy before the chemotherapy, and we have seen that preexisting neuropathy was a key CIPN risk factor.

The number of chemotherapy cycles received was a strong predictor both in univariate and multivariate analyses. This is not linked with cumulative dose (as the latter was not shown to be predictive of CIPN in our study). Hence, this finding may imply that "time" after starting chemotherapy may be strongly linked with the development of CIPN, suggesting that CIPN is time‐dependent rather than dose‐dependent, although the link between cumulative dose and CIPN has been reported in past literature but not consistently (Seretny et al., [2014](#brb31312-bib-0027){ref-type="ref"}).

Two parameters in the final predictive model need some more consideration in the development of CIPN. Firstly, the role of hepatitis (possibly as a result of taking neurotoxic antiviral agents in the past or even as a result of disturbance in the pharmacokinetics of the chemotherapy drugs, i.e., decreased liver function and/or increased drug exposition). Secondly, current smoking with perhaps its connection with pain pathways. Both of them had very high odds ratios (3.93 and 1.18--2.54, respectively) but both these ORs were not statistically significant, highly likely as a result of the small number of patients reporting these two variables (*n* = 13 and 7, respectively). Future research should provide more insight about the potential risk for CIPN for hepatitis and smoking status.

Some variables in the study had small frequency counts, and this may affect the interpretation and generalizability of the results and should be perceived as preliminary only. Identification of risk factors may assist the clinician to make chemotherapy treatment decisions accordingly in order to minimize not only the development of CIPN but also the morbidity and health care utilization linked with higher incidence of CIPN (while clinical effectiveness is not compromized). However, the state of science in this area is not yet optimal for such clinical decisions, and more research in elucidating strong CIPN‐related risk factors is needed, including the development of predictive models. Other consistent risk factors, such as higher BMI and obesity were not assessed in this study and these should be included in future models.

This study confirms the role of (older) age; number of chemotherapy cycles received, and type of chemotherapy as key CIPN risk factors. The role of past neuropathic damage specifically linked with motor CIPN and (chronic) alcohol consumption are also important new variables to consider alongside the presence of symptom burden/specific symptoms that may form a symptom cluster around neuropathy. Risk factor knowledge can assist health professionals in educating patients in a more targeted way about this symptom experience and introduce more regular assessment of CIPN particularly in those at higher risk, in order to monitor its development and the impact it may have on patients' quality of life. Preventive interventions may need to be initiated to those with high risk of CIPN.
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